EIKON THERAPEUTICS, INC. Stock-Based Compensation
EIKON THERAPEUTICS, INC. (EIKN) reported Stock-Based Compensation of $7.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- EIKON THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $4.22M, a 41.51% decline year-over-year.
- EIKON THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.78M, a 6.50% decline year-over-year.
- EIKON THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $7.21M.
- EIKON THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $2.97M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month |
|---|---|---|
| 2026-06-30 | $4.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $7.00M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.78M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $7.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $10.18M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $2.97M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |